[CAS NO. 1383982-64-6]  Lanabecestat (AZD3293)

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1383982-64-6]

Store
Catalog
SLK-S8193
Brand
Selleck
CAS
1383982-64-6

DESCRIPTION [1383982-64-6]

Overview

MDL-
Molecular Weight412.53
Molecular FormulaC26H28N4O
SMILES-

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

1 mg5 mg10 mg
1 mM2.4241 mL12.1203 mL24.2407 mL
5 mM0.4848 mL2.4241 mL4.8481 mL
10 mM0.2424 mL1.2120 mL2.4241 mL
50 mM0.0485 mL0.2424 mL0.4848 mL

Description

Lanabecestat (AZD3293, LY3314814) is an oral inhibitor with an inhibitory constant Ki  of 0.4 nM.

Targets

BACE [1]
(Cell-free assay)
0.4 nM(Ki)

In vitro

Lanabecestat(AZD3293, LY3314814)is a potent, highly permeable, orally active, blood-brain barrier (BBB) penetrating, BACE1 inhibitor with unique slow off-rate kinetics. When the potency of AZD3293 with respect to secretion of Aβ40 and sAβPPβ is studied in a range of cellular models, the compound displays pM potency in primary neuron cultures from mice and guinea pigs and in SH-SY5Y cells over-expressing AβPP (IC50 = 610 pM, 310 pM, and 80 pM, respectively). AZD3293 is also tested in a panel of more than 350 in vitro radioligand binding and enzyme activity assays, covering a diverse range of receptors, ion channels, transporters, kinases, and enzymes, up to a concentration of 10μM of AZD3293. A few significant responses are observed, but these had at least a 1,000-fold selectivity against BACE1, thus indicating specificity to BACE1. The off-rate of AZD3293 has an estimated t of approximately 9 h.

In vivo

In vivo in mice, guinea pigs, and dogs, AZD3293 displays significant dose- and time-dependent reductions in plasma, cerebrospinal fluid, and brain concentrations of Aβ40, Aβ42, and sAβPPβ. In the dog PK study, the bioavailability of AZD3293 is determined to be 80% (F = 0.8). The preclinical data strongly support the clinical development of AZD3293, and patients with AD are currently being recruited into a combined Phase 2/3 study to test the disease-modifying properties of AZD3293.